{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:09:24Z","timestamp":1790863764028,"version":"4.1.0"},"reference-count":105,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Romania"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Diabetes is a complex global healthcare burden involving multiple organ systems with its prevalence on the rise. SGLT2 inhibitors enhance glucose excretion. The objective of our literature review was to determine the association between cutaneous adverse drug reactions (CADRs) and the use of SGLT2 inhibitors. We collected data on CADRs related to the use of SGLT2 inhibitors from all available published articles and studied their details to understand the patterns of their association. PubMed, Cochrane, Google, and Embase were searched for relevant articles. A total of 37 papers were included and studied. Most articles were case reports followed by pharmacovigilance studies, case series, and reviews. The cutaneous findings ranged from benign eruptions to severe reactions. The available literature suggests a strong link between the use of SGLT2 inhibitors and Fournier\u2019s gangrene\/necrotizing fasciitis. T2DM patients using SGLT2 inhibitors have also developed fixed drug eruptions, drug-induced pruritus, and Sweet syndrome\/acute febrile neutrophilic dermatosis, among other skin lesions. We found that SGLT2 inhibitors present a risk of developing CADRs. Raising awareness among healthcare providers regarding CADRs to SGLT2 inhibitors can reduce complications, minimize hospitalizations, and improve patient care in the vulnerable population of diabetes patients.<\/jats:p>","DOI":"10.3390\/jcm14010188","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:51:57Z","timestamp":1735631517000},"page":"188","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors"],"prefix":"10.3390","volume":"14","author":[{"given":"Alexandra Laura","family":"Mederle","sequence":"first","affiliation":[{"name":"Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dumitrescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Borza","sequence":"additional","affiliation":[{"name":"Discipline of Pathophysiology, Department of Functional Science, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Center for Translational Research and Systems Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Centre of Cognitive Research in Pathological Neuro-Psychiatry NEUROPSY-COG, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-7182","authenticated-orcid":false,"given":"Nilima Rajpal","family":"Kundnani","sequence":"additional","affiliation":[{"name":"Department of Cardiology\u2014Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Research Centre of Timi\u0219oara Institute of Cardiovascular Diseases, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref_1","unstructured":"International Diabetes Federation (2024, November 01). IDF Diabetes Atlas 2019. Available online: https:\/\/diabetesatlas.org\/atlas\/ninth-edition\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2014.10.2819","article-title":"Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes","volume":"126","author":"Davidson","year":"2014","journal-title":"Postgrad. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jabbour, S.A., Ibrahim, N.E., and Argyropoulos, C.P. (2022). Physicians\u2019 Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors. J. Clin. Med., 11.","DOI":"10.3390\/jcm11206051"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.4155\/fmc-2018-0514","article-title":"The effect of SGLT-2 inhibitors on blood pressure: A pleiotropic action favoring cardio- and nephroprotection","volume":"11","author":"Loutradis","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14797\/mdcvj.1120","article-title":"SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review","volume":"18","author":"Kansara","year":"2022","journal-title":"Methodist. Debakey Cardiovasc. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Qiu, M., Zhao, L.M., and Zhan, Z.L. (2021). Comprehensive Analysis of Adverse Events Associated with SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.743807"},{"key":"ref_11","first-page":"18","article-title":"SGLT2 inhibitors and heart failure outcomes","volume":"45","author":"Chim","year":"2020","journal-title":"US Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ajh\/hpx204","article-title":"Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects","volume":"31","author":"Pioli","year":"2018","journal-title":"Am. J. Hypertens."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Liu, J., Li, L., Li, S., Jia, P., Deng, K., Chen, W., and Sun, X. (2017). Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-02733-w"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK prospective diabetes study (UKPDS): Clinical and therapeutic implications for type 2 diabetes","volume":"48","author":"King","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1574886313666180226103408","article-title":"Risks Associated with SGLT2 Inhibitors: An Overview","volume":"13","author":"Singh","year":"2018","journal-title":"Curr. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e000725","DOI":"10.1136\/bmjdrc-2019-000725","article-title":"Pharmacovigilance assessment of the association between Fournier\u2019s gangrene and other severe genital adverse events with SGLT-2 inhibitors","volume":"7","author":"Fadini","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41574-019-0275-6","article-title":"SGLT2 inhibitors and urinary tract infections","volume":"15","author":"Wilding","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhang, Y.S., Zheng, Y.D., Yuan, Y., Chen, S.C., and Xie, B.C. (2021). Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.735824"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic Diabetic Ketoacidosis: A Review","volume":"13","author":"Modi","year":"2017","journal-title":"Curr. Diabetes Rev."},{"key":"ref_20","first-page":"17-0081","article-title":"Euglycemic diabetic ketoacidosis: A diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla","year":"2017","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7074868","DOI":"10.1155\/2018\/7074868","article-title":"Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis","volume":"2018","author":"Yu","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/dc15-1251","article-title":"Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program","volume":"38","author":"Erondu","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment with Sodium-Glucose Cotransporter 2 Inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc. Dis. Res."},{"key":"ref_26","first-page":"A5316","article-title":"Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state\u2014A systematic review","volume":"64","author":"Bustan","year":"2017","journal-title":"Dan. Med. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S637","DOI":"10.1067\/mai.2000.106156","article-title":"Understanding drug allergies","volume":"105","author":"Gruchalla","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3949\/ccjm.75.11.772","article-title":"Skin manifestations of diabetes","volume":"75","author":"Bootsma","year":"2008","journal-title":"Cleve Clin. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mieczkowski, M., Mrozikiewicz-Rakowska, B., Kowara, M., Kleibert, M., and Czupryniak, L. (2022). The Problem of Wound Healing in Diabetes\u2014From Molecular Pathways to the Design of an Animal Model. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147930"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2337\/diabetes.50.7.1627","article-title":"Glucose effects on skin keratinocytes: Implications for diabetes skin complications","volume":"50","author":"Spravchikov","year":"2001","journal-title":"Diabetes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/diabetology3010008","article-title":"Cutaneous Reactions to Antidiabetic Agents: A Narrative Review","volume":"3","author":"Boccardi","year":"2022","journal-title":"Diabetology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0019-5154.39732","article-title":"Adverse cutaneous drug reaction","volume":"53","author":"Nayak","year":"2008","journal-title":"Indian. J. Dermatol."},{"key":"ref_33","unstructured":"Al Aboud, D.M., Nessel, T.A., and Hafsi, W. (2024, November 01). Cutaneous Adverse Drug Reaction, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK533000\/."},{"key":"ref_34","unstructured":"Maan, M.A., Naureen, S., and Saddiqua, A. (2010). Anxiety, Depression and Self-Esteem Among Chronic Skin Patients, Annals of Punjab Medical College."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: A cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000490002","article-title":"Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease","volume":"31","author":"Farzanfar","year":"2018","journal-title":"Skin. Pharmacol. Physiol."},{"key":"ref_37","unstructured":"Cecilia-Chi, W.C., and Lim-Tio, S. (2024, December 27). Fournier\u2019s Syndrome: A Life Threatening Complication of SGLT2 Inhibition in Poorly Controlled Diabetes Mellitus. In Proceedings of the Joint Annual Scientific Meeting of the Australian Diabetes Educators Association and Australian Diabetes Society, Gold Coast, Queensland, Australia; pp. 24\u201326. Available online: https:\/\/ads-adea-2016.m.asnevents.com.au\/schedule\/session\/9239\/abstract\/36604."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/dme.13508","article-title":"Fournier\u2019s gangrene in a man on empagliflozin for treatment of Type 2 diabetes","volume":"34","author":"Kumar","year":"2017","journal-title":"Diabet. Med."},{"key":"ref_39","first-page":"97","article-title":"SLGT-2 inhibitor dapagliflozin and Fournier\u2019s gangrene: A life-threatening severe adverse effect","volume":"35","author":"Omer","year":"2018","journal-title":"Diabet. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/1753-0407.12896","article-title":"Fournier\u2019s gangrene in a patient on dapagliflozin treatment for type 2 diabetes","volume":"11","author":"Onder","year":"2019","journal-title":"J. Diabetes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40800-019-0105-8","article-title":"Fournier\u2019s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report","volume":"6","author":"Nagano","year":"2019","journal-title":"Drug Saf. Case Rep."},{"key":"ref_42","first-page":"e5778","article-title":"Fournier\u2019s Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature","volume":"11","author":"Rodler","year":"2019","journal-title":"Cureus"},{"key":"ref_43","first-page":"e5173","article-title":"Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review","volume":"11","author":"Elshimy","year":"2019","journal-title":"Cureus"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e920115","DOI":"10.12659\/AJCR.920115","article-title":"A Case of Fournier\u2019s Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus","volume":"21","author":"Elbeddini","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijscr.2020.11.100","article-title":"Fournier\u2019s gangrene under SGLT-2 inhibitor therapy: A literature review and case report","volume":"77","author":"Prytz","year":"2020","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.endinu.2019.12.007","article-title":"Fournier\u2019s gangrene and SGLT2 inhibitors: A case study","volume":"67","year":"2020","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e921536","DOI":"10.12659\/AJCR.921536","article-title":"Fournier\u2019s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications","volume":"21","author":"Kasbawala","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.3393\/ac.2020.06.22","article-title":"Fournier Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Case Report","volume":"37","author":"Moon","year":"2021","journal-title":"Ann. Coloproctol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Suciu, I.M., Grelu\u0219, A., Cozlac, A.R., Suciu, B.S., Stoica, S., Luca, S., Luca, C.T., and Gai\u021b\u0103, D.I. (2024). Fournier\u2019s Gangrene as an Adverse Event Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors. Medicina, 60.","DOI":"10.3390\/medicina60050837"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3695101","DOI":"10.1155\/2020\/3695101","article-title":"Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System","volume":"2020","author":"Hu","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13300-020-00771-8","article-title":"SGLT2 Inhibitors and the Risk of Hospitalization for Fournier\u2019s Gangrene: A Nested Case-Control Study","volume":"11","author":"Wang","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2337\/cd21-0015","article-title":"Sodium-Glucose Cotransporter 2 Inhibitor Use Associated with Fournier\u2019s Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases","volume":"40","author":"Tran","year":"2022","journal-title":"Clin. Diabetes"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.25179\/tjem.2018-63449","article-title":"case report: Fixed drug eruption caused by dapagliflozin","volume":"23","author":"Keskin","year":"2019","journal-title":"Turk. J. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.jdiacomp.2016.08.002","article-title":"Possible new inflammatory side-effect of SGLT2-inhibitors: Fixed drug eruption","volume":"30","author":"Damiani","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/ajd.12502","article-title":"First case of drug eruption due to ipragliflozin: Case report and review of the literature","volume":"58","author":"Sawada","year":"2017","journal-title":"Australas. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/14740338.2015.1034105","article-title":"Short-term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: Considerations for their appropriate use to avoid serious adverse events","volume":"14","author":"Yabe","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"937","DOI":"10.7150\/ijms.22224","article-title":"Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors","volume":"15","author":"Sakaeda","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1574886311666160405110515","article-title":"Generalized Intense Pruritus During Canagliflozin Treatment: Is. it an Adverse Drug Reaction?","volume":"13","author":"Vasapollo","year":"2018","journal-title":"Curr. Drug Saf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"E1651","DOI":"10.1503\/cmaj.220934","article-title":"Drug eruption associated with empagliflozin","volume":"194","author":"Yau","year":"2022","journal-title":"CMAJ"},{"key":"ref_60","first-page":"e17573","article-title":"Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers","volume":"13","author":"Ali","year":"2021","journal-title":"Cureus"},{"key":"ref_61","first-page":"E22","article-title":"Dapagliflozin-induced sweet syndrome","volume":"104","author":"Mattis","year":"2019","journal-title":"Cutis"},{"key":"ref_62","first-page":"59","article-title":"A Case of Bullous Pemphigoid Associated with the Administration of Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor","volume":"61","author":"Ikehara","year":"2018","journal-title":"J. Jpn. Diabetes Soc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/ced.15385","article-title":"Association between sodium-glucose co-transporter 2 inhibitors and risk of psoriasis in patients with diabetes mellitus: A nationwide population-based cohort study","volume":"47","author":"Ma","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/ijd.16449","article-title":"Gliflozin (SGLT2 inhibitor) induced vulvitis","volume":"62","author":"Mounsey","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","article-title":"Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems","volume":"27","author":"Raschi","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases","volume":"170","author":"Chamberlain","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40261-016-0438-3","article-title":"Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis","volume":"36","author":"Mellander","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/00325481.2018.1394152","article-title":"SGLT2 inhibitors: Are they safe?","volume":"130","author":"Filippatos","year":"2018","journal-title":"Postgrad. Med."},{"key":"ref_69","unstructured":"(2024, October 11). FDA Adverse Events Reporting System (FAERS), Available online: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/45beeb74-30ab-46be-8267-5756582633b4\/state\/analysis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/pgmj.2005.042069","article-title":"Fournier\u2019s gangrene and its emergency management","volume":"82","author":"Thwaini","year":"2006","journal-title":"Postgrad. Med. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"942437","DOI":"10.5402\/2012\/942437","article-title":"Fournier\u2019s Gangrene: Current Practices","volume":"2012","author":"Mallikarjuna","year":"2012","journal-title":"ISRN Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1749-7922-8-13","article-title":"Fournier\u2019s gangrene: Our experience with 50 patients and analysis of factors affecting mortality","volume":"8","author":"Souiki","year":"2013","journal-title":"World J. Emerg. Surg."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijid.2019.12.030","article-title":"Fournier\u2019s gangrene mortality: A 17-year systematic review and meta-analysis","volume":"92","author":"Khalaf","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4081\/aiua.2016.3.157","article-title":"Fournier\u2019s gangrene. A clinical review","volume":"88","author":"Singh","year":"2016","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13611","article-title":"A safety update on sodium glucose co-transporter 2 inhibitors","volume":"21","author":"Fitchett","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/0970-1591.117255","article-title":"Prospective evaluation of risk factors for mortality in patients of Fournier\u2019s gangrene: A single center experience","volume":"29","author":"Vyas","year":"2013","journal-title":"Indian. J. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.urology.2012.12.041","article-title":"Causative pathogens, antibiotic sensitivity, resistance patterns, and severity in a contemporary series of Fournier\u2019s gangrene","volume":"81","author":"Bjurlin","year":"2013","journal-title":"Urology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1634\/theoncologist.2012-0066","article-title":"Body mass index and risk of primary liver cancer: A meta-analysis of prospective studies","volume":"17","author":"Wang","year":"2012","journal-title":"Oncologist"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.juro.2009.01.034","article-title":"Fournier\u2019s Gangrene: Population based epidemiology and outcomes","volume":"181","author":"Sorensen","year":"2009","journal-title":"J. Urol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.urology.2017.10.031","article-title":"Presentation and Diagnosis of Fournier Gangrene","volume":"114","author":"Voelzke","year":"2018","journal-title":"Urology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.urology.2014.08.063","article-title":"A contemporary analysis of Fournier gangrene using the National Surgical Quality Improvement Program","volume":"85","author":"Kim","year":"2015","journal-title":"Urology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2340\/00015555-0650","article-title":"Drug-induced pruritus: A review","volume":"89","author":"Reich","year":"2009","journal-title":"Acta Derm. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., Sango, K., and Utsunomiya, K. (2017). SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051083"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int."},{"key":"ref_86","first-page":"e3490","article-title":"Bullous Variant of Sweet\u2019s Syndrome as a Consequence of Radioiodine Contrast Exposure","volume":"10","author":"Bhat","year":"2018","journal-title":"Cureus"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.4103\/jfmpc.jfmpc_289_18","article-title":"Not so sweet; severe Sweet\u2019s syndrome presenting as SIRS and pleural effusion","volume":"7","author":"Vettakkara","year":"2018","journal-title":"J. Family Med. Prim. Care"},{"key":"ref_88","unstructured":"Vashisht, P., Goyal, A., and Hearth Holmes, M.P. (2024). Sweet Syndrome. StatPearls, StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamadermatol.2018.3890","article-title":"Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis","volume":"155","author":"Sanchez","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_90","first-page":"167","article-title":"Diagnostic criteria for Sweet\u2019s syndrome","volume":"37","author":"Su","year":"1986","journal-title":"Cutis"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-2-34","article-title":"Sweet\u2019s syndrome\u2014A comprehensive review of an acute febrile neutrophilic dermatosis","volume":"2","author":"Cohen","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.cmi.2015.03.024","article-title":"Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: Focus on skin and soft-tissue infections","volume":"21","author":"Dryden","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1464-5491.1995.tb00396.x","article-title":"Neutrophil bactericidal function in diabetes mellitus: Evidence for association with blood glucose control","volume":"12","author":"Gallacher","year":"1995","journal-title":"Diabet. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.ijid.2010.10.003","article-title":"The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: Results from three randomized controlled trials","volume":"15","author":"Lipsky","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/427690","article-title":"Serious infections in elderly patients with diabetes mellitus","volume":"40","author":"Rajagopalan","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Suresh, S., Naik, A., and Premanath, R. (2023). Glucose-Induced Enhanced Virulence in Strains of Multidrug-Resistant Pseudomonas aeruginosa Isolated from Diabetic Patients. Curr. Microbiol., 80.","DOI":"10.1007\/s00284-023-03200-8"},{"key":"ref_98","first-page":"83","article-title":"Metformin as a Potential Adjuvant Antimicrobial Agent Against Multidrug Resistant Bacteria","volume":"13","author":"Masadeh","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e2975","DOI":"10.1002\/dmrr.2975","article-title":"Is metformin poised for a second career as an antimicrobial?","volume":"34","author":"Malik","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e011523","DOI":"10.1136\/bmjopen-2016-011523","article-title":"Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: A Danish nationwide population-based cohort study","volume":"6","author":"Mor","year":"2016","journal-title":"BMJ Open"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Shih, C.J., Wu, Y.L., Chao, P.W., Kuo, S.C., Yang, C.Y., Li, S.Y., Ou, S.M., and Chen, Y.T. (2015). Association between Use of Oral Anti-Diabetic Drugs and the Risk of Sepsis: A Nested Case-Control Study. Sci. Rep., 5.","DOI":"10.1038\/srep15260"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Milder, T.Y., Stocker, S.L., Abdel Shaheed, C., McGrath-Cadell, L., Samocha-Bonet, D., Greenfield, J.R., and Day, R.O. (2019). Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010045"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2019.01.002","article-title":"SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes","volume":"846","author":"Donnan","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Valinciute-Jankauskiene, A., and Kubiliene, L. (2021). Adverse Drug Reaction Reporting by Patients in 12 European Countries. Int. J. Environ. Res. Public. Health, 18.","DOI":"10.3390\/ijerph18041507"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s11096-023-01592-y","article-title":"Factors associated with underreporting of adverse drug reactions by patients: A systematic review","volume":"45","author":"Costa","year":"2023","journal-title":"Int. J. Clin. Pharm."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/1\/188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:58:00Z","timestamp":1760115480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/1\/188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["jcm14010188"],"URL":"https:\/\/doi.org\/10.3390\/jcm14010188","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}